Adjunctive moxifloxacin in the treatment of generalized aggressive periodontitis patients: clinical and microbiological results of a randomized, triple-blind and placebo-controlled clinical trial

Aim The aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one‐stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP). Materials and Methods Forty subjects were randomly allocated to two treatment groups....

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of clinical periodontology Ročník 42; číslo 2; s. 160 - 168
Hlavní autori: Ardila, Carlos Martín, Martelo-Cadavid, Juan Felipe, Boderth-Acosta, Gina, Ariza-Garcés, Astrid Adriana, Guzmán, Isabel C.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Blackwell Publishing Ltd 01.02.2015
Predmet:
ISSN:0303-6979, 1600-051X, 1600-051X
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Aim The aim of the present study was to evaluate the clinical and microbiological efficacy of moxifloxacin (MOX) in one‐stage scaling and root planing (SRP) in treating generalized aggressive periodontitis (GAgP). Materials and Methods Forty subjects were randomly allocated to two treatment groups. The two treatment groups consisted of SRP combined with systemically admi‐nistered MOX at the dosage of 400 mg once daily for 7 days or SRP + placebo once daily for 7 days. Subgingival plaque samples were analysed for cultivable bacteria. Results Both groups resulted in significant reduction of probing depth (PD) and clinical attachment level (CAL) compared with baseline (p < 0.0001), and this difference was maintained at 6 months from baseline in both groups. However, subjects receiving MOX showed the greatest improvements CAL, and PD. Subjects in both groups at 6 months displayed the greatest reduction from baseline in frequency of sites with PD ≥6 mm (p < 0.001), favouring the MOX group. Adjunctive antibiotic protocol reduced subgingival Aggregatibacter actinomycetemcomitans to undetectable levels, after 3 and 6 months, and there was a significant reduction in the levels of Porphyromonas gingivalis and Tannerella forsythia in the MOX group compared to the placebo group. Conclusions The results from this study suggest that moxifloxacin as and adjunct to one‐stage full‐mouth SRP leads to a better clinical and microbiological advantages compared to mechanical treatment.
Bibliografia:School of Dentistry of the Universidad de Antioquia, Medellín, Colombia - No. NCT02125812
ArticleID:JCPE12345
ark:/67375/WNG-RKWTRBZV-0
istex:5B95F2A19E2E96572A904DF7C57356D3522CC637
The authors declare that they have no conflict of interest in relation to this investigation. The School of Dentistry of the Universidad de Antioquia, Medellín, Colombia financed the study.
Conflict of interest and source of funding statement
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0303-6979
1600-051X
1600-051X
DOI:10.1111/jcpe.12345